Real-world Experiences with Brentuximab Vedotion-based Regimens in Systemic Anaplastic Large Cell Lymphoma: a Multi-center Retrospective Study

Overview

Journal Front Oncol

Date 2025 Jan 22

PMID 39839780

Authors

Zhiqiang Zhao

Qinchuan Yu

Liping Su

Jianxia He

Jie Tao

Yanfeng Xi

Yujiao Guo

Yanhong Luo

Lieyang Wang

Affiliations

Soon will be listed here.

Abstract

Background: Brentuximab vedotin (BV) has demonstrated high remission rates in clinical trials for systemic anaplastic large cell lymphoma (sALCL), yet its real-world effectiveness in China remains unconfirmed. This retrospective observational study evaluates BV-based regimens in patients with sALCL, treated from 2020 to 2023.

Methods: A multi-center observational retrospective study was conducted on patients with sALCL received BV plus cyclophosphamide, doxorubicin, and prednisone (CHP) upfront or BV plus gemcitabine, oxaliplatin(GemOx), gemcitabine, cisplatin, dexamethasone(GDP), or isocyclophosphamide, carboplatin, etoposide (ICE)for later lines. Primary endpoints were complete response rate (CRR) and overall response rate (ORR); secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DOR), and the incidence of adverse events (AEs).

Results: Among the 38 patients (28 newly diagnosed and 10 with refractory/relapsed disease), the ORR were 100% (with 89.3% CR) for newly diagnosed patients and 70% (with 50% CR) for refractory/relapsed patients. The median duration of response was 14 months for newly diagnosed patients and 23.8 months for those with refractory/relapsed disease. 2-year Survival rates were 100% for newly diagnosed patients and 80% for refractory/relapsed patients, with 2-year PFS rates of 92.8% and 70%, respectively. Neurological toxicities were commonly observed but resolved following the completion of treatment.

Conclusion: BV has proven to be effective and well-tolerated in real-world settings for the treatment of sALCL, reinforcing its potential as a promising option for first-line or subsequent therapy. The sustained efficacy observed post-CR suggests that these patients may have a prolonged disease control.

References

Kung Sutherland M, Sanderson R, Gordon K, Andreyka J, Cerveny C, Yu C . Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006; 281(15):10540-7. DOI: 10.1074/jbc.M510026200. View

Ishizawa K, Yanai T . Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma. Adv Ther. 2019; 36(10):2679-2696. PMC: 6822829. DOI: 10.1007/s12325-019-01046-w. View

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

Horwitz S, OConnor O, Pro B, Trumper L, Iyer S, Advani R . The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2021; 33(3):288-298. PMC: 9447792. DOI: 10.1016/j.annonc.2021.12.002. View

Contarini G, Carraro E, Lovisa F, Martire G, Lo Nigro L, Sala A . Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series. Br J Haematol. 2023; 204(1):352-355. DOI: 10.1111/bjh.19151. View

Kim S, Do Y, Lee H, Lee W, Kong J, Kwak J . A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study. Blood Res. 2023; 58(4):194-200. PMC: 10758628. DOI: 10.5045/br.2023.2023206. View

Afable M, Caimi P, Hosing C, de Lima M, Khouri I, William B . Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biol Blood Marrow Transplant. 2015; 21(8):1529-1531. PMC: 4830276. DOI: 10.1016/j.bbmt.2015.04.022. View

Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T . Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017; 130(25):2709-2717. PMC: 5746164. DOI: 10.1182/blood-2017-05-780049. View

Fukuhara N, Yamamoto G, Tsujimura H, Chou T, Shibayama H, Yanai T . Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma. 2019; 61(1):176-180. DOI: 10.1080/10428194.2019.1654100. View

10.

Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G . Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica. 2017; 102(11):1931-1935. PMC: 5664397. DOI: 10.3324/haematol.2017.171355. View

11.

Koh K, Im H, Suh J, Lee S, Choi E, Seo J . Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation. Pediatr Blood Cancer. 2015; 62(6):1063-5. DOI: 10.1002/pbc.25351. View

12.

Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30(18):2190-6. DOI: 10.1200/JCO.2011.38.0402. View

13.

Izutsu K, Ogura M, Tobinai K, Hatake K, Sakamoto S, Nishimura M . Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study. Int J Hematol. 2021; 113(3):404-412. PMC: 7779085. DOI: 10.1007/s12185-020-03039-w. View

14.

Halligan S, Grainge M, Martinez-Calle N, Fox C, Bishton M . Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data. Br J Haematol. 2021; 196(4):932-938. DOI: 10.1111/bjh.17896. View

15.

Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S . Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018; 5(10):e450-e461. DOI: 10.1016/S2352-3026(18)30153-4. View

16.

Gandolfi L, Pellegrini C, Casadei B, Stefoni V, Broccoli A, Tonialini L . Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. Oncologist. 2016; 21(12):1436-1441. PMC: 5153337. DOI: 10.1634/theoncologist.2016-0112. View

17.

Okeley N, Miyamoto J, Zhang X, Sanderson R, Benjamin D, Sievers E . Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010; 16(3):888-97. DOI: 10.1158/1078-0432.CCR-09-2069. View

18.

Agrusa J, Egress E, Lowe E . Brentuximab vedotin use in pediatric anaplastic large cell lymphoma. Front Immunol. 2023; 14:1203471. PMC: 10232850. DOI: 10.3389/fimmu.2023.1203471. View

19.

Kaimi Y, Takahashi Y, Taniguchi H, Ochi T, Makino H, Makita S . Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy. Virchows Arch. 2024; 484(3):465-473. DOI: 10.1007/s00428-024-03764-1. View

20.

Bartlett N, Chen R, Fanale M, Brice P, Gopal A, Smith S . Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014; 7:24. PMC: 3994656. DOI: 10.1186/1756-8722-7-24. View